Foresite Capital Management V LLC Purchases New Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Foresite Capital Management V LLC acquired a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 8,133,047 shares of the company's stock, valued at approximately $5,205,000. Lyell Immunopharma accounts for 4.3% of Foresite Capital Management V LLC's holdings, making the stock its 6th largest holding. Foresite Capital Management V LLC owned 2.78% of Lyell Immunopharma at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. grew its position in shares of Lyell Immunopharma by 104.4% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 966,265 shares of the company's stock worth $618,000 after buying an additional 493,639 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Lyell Immunopharma in the 4th quarter worth approximately $162,000. Almitas Capital LLC purchased a new stake in shares of Lyell Immunopharma in the 4th quarter worth approximately $672,000. Decheng Capital LLC bought a new position in Lyell Immunopharma during the 4th quarter valued at approximately $7,622,000. Finally, Boothbay Fund Management LLC increased its position in Lyell Immunopharma by 190.4% during the 4th quarter. Boothbay Fund Management LLC now owns 406,234 shares of the company's stock valued at $260,000 after buying an additional 266,354 shares in the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Stock Up 1.8%

Lyell Immunopharma stock traded up $0.01 during trading hours on Thursday, hitting $0.40. The stock had a trading volume of 230,474 shares, compared to its average volume of 1,036,842. The stock's 50-day moving average price is $0.48 and its 200-day moving average price is $0.67. The stock has a market capitalization of $117.25 million, a P/E ratio of -0.50 and a beta of -0.25. Lyell Immunopharma, Inc. has a 12-month low of $0.39 and a 12-month high of $2.88.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01. The firm had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. On average, research analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Insider Buying and Selling at Lyell Immunopharma

In related news, Director Richard Klausner purchased 158,000 shares of the business's stock in a transaction on Friday, March 14th. The stock was acquired at an average price of $0.60 per share, with a total value of $94,800.00. Following the completion of the acquisition, the director now owns 843,365 shares of the company's stock, valued at approximately $506,019. This trade represents a 23.05% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Lynn Seely acquired 175,000 shares of the firm's stock in a transaction dated Friday, March 14th. The shares were purchased at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the completion of the transaction, the chief executive officer now directly owns 712,500 shares in the company, valued at approximately $434,625. This trade represents a 32.56% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 768,640 shares of company stock worth $449,508. Insiders own 25.10% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "neutral" rating and issued a $1.00 target price on shares of Lyell Immunopharma in a report on Wednesday, April 16th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.